Your browser doesn't support javascript.
loading
SARS-CoV-2 serological testing using electrochemiluminescence reveals arapid onset of seroconversion in severe COVID-19 patients
Ariel Munitz; Liat Edry-Botzer; Michal Itan; Ran Tur-Kaspa; Dror Dicker; Dana Markovitch; Moran Goren; Michael Mor; Shuval Lev; Tamar Gottesman; Khitam Muhsen; Daniel Cohen; Miguel Stein; Udi Qimron; Natalia Freund; Yariv Wine; Motti Gerlic.
Afiliación
  • Ariel Munitz; Department of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel.
  • Liat Edry-Botzer; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Michal Itan; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Ran Tur-Kaspa; Department of Medicine D and the Liver Institute, Rabin Medical Center, Beilinson Hospital, Molecular Hepatology Research Laboratory, Felsenstein Medical Resear
  • Dror Dicker; Internal Medicine D, Hasharon Hospital-Rabin Medical Center, Petach Tikva, Israel. Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Dana Markovitch; Internal Medicine D, Hasharon Hospital-Rabin Medical Center, Petach Tikva, Israel. Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Moran Goren; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Michael Mor; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Shuval Lev; Intensive care unit, Hasharon Hospital-Rabin Medical Center, Petach Tikva, Israel. Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Tamar Gottesman; Infectious diseases and infection control, Hasharon Hospital-Rabin Medical Center, Petach Tikva, Israel. Sackler School of Medicine, Tel Aviv University, 699780
  • Khitam Muhsen; Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University, 6997801 Israel
  • Daniel Cohen; Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv University, 6997801 Israel
  • Miguel Stein; Allergy and Immunology Unit, Wolfson Medical Center, 6997801 Israel
  • Udi Qimron; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Natalia Freund; Department of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, 6997801 Israel
  • Yariv Wine; School of Molecular Cell Biology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, 6997801 Israel
  • Motti Gerlic; Department of Clinical Microbiology and Immunology, The Sackler School of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel.
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20141838
ABSTRACT
Despite ongoing efforts to characterize the host response toward SARS-CoV-2, a major gap in our knowledge still exists regarding the magnitude and duration of the humoral response. We report the development of a rapid, highly specific and sensitive electrochemiluminescent assay for detecting IgM, IgA, and IgG antibodies toward two distinct SARS-CoV-2 antigens namely, the receptor binding domain (RBD) and the nuclear protein (NP). Whereas IgM antibodies toward RBD were detected at early stages of the disease, IgM antibodies against NP did not develop. Analysis of the antibody response in mild versus moderate/severe patients revealed a rapid onset of IgG and IgA antibodies, specifically in moderate/severe patients. Finally, we observed a marked reduction in IgM/IgA antibodies and to lesser extent, IgG, over time. We provide a comprehensive analysis of the human antibody response, and has major implications on our understanding and monitoring of SARS-CoV-2 infections, as well as finding effective vaccines. One Sentence SummaryUsing a newly developed assay to detect anti-SARS-Cov-2 IgM, IgG and IgA antibodies we reveal a rapid onset of IgG and IgA antibodies towards distinct viral antigens, specifically in moderate/severe COVID-19 patients,
Licencia
cc_by_nc_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Diagnostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Diagnostic_studies Idioma: En Año: 2020 Tipo del documento: Preprint